AZmed vs Infervision (2026)
Two non United States imaging vendors reading different films for different departments. AZmed is trauma first, detecting fractures, effusions and dislocations on plain radiographs, aimed at the emergency queue where a missed finding most reliably becomes a complaint, with a clearance covering adult and paediatric use that is reported to be unique in that segment. Infervision spans lung nodule detection and chest interpretation across modalities with United States operations alongside its origin market. They barely overlap clinically, so the choice is which reading burden you are attacking. Both fit the pattern this index records for non Western imaging vendors: thorough regulatory dossiers, thin commercial assurance, so ask for attestations directly.
- It is trauma first, detecting fractures, joint effusions and dislocations, which is the highest volume plain film reading in any emergency department.
- The fracture clearance covers both adult and paediatric use, reported to be unique in that segment, with a strong clearance study design.
- Distribution runs directly and through several imaging platform partners, so adoption does not depend on one integration route.
- Its suite spans lung nodule detection and chest interpretation with United States operations alongside its origin market.
- Coverage extends across modalities rather than radiography alone, so one vendor reaches more of the imaging estate.
- For a buyer wanting an established American support relationship from a non Western vendor, that presence matters.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. AZmed and Infervision are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | AZmed | Infervision |
|---|---|---|
| Primary category | Radiology & Imaging AI | Radiology & Imaging AI |
| Founded | 2018 | 2015 |
| Headquarters | Paris, France | Beijing, China |
| Website | azmed.co | global.infervision.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards AZmed its top capability grade on AI Centrality, Clinical and Operational Evidence and FDA and Regulatory Status. Set against Infervision, AZmed grades higher on several axes, including Model and Technology Transparency, Model Supply Chain Disclosure and Clinical and Operational Evidence. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Infervision its top capability grade on AI Centrality, FDA and Regulatory Status and Setting and Specialty Coverage. Set against AZmed, Infervision grades higher on Setting and Specialty Coverage. Its thinnest published disclosure sits on Model Supply Chain Disclosure and AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose AZmed or Infervision?
On the axes where the AI Health Index separates them, AZmed grades higher on several axes, including Model and Technology Transparency, Model Supply Chain Disclosure and Clinical and Operational Evidence, and Infervision grades higher on Setting and Specialty Coverage. AZmed leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do AZmed and Infervision differ most?
The widest separation the AI Health Index records between AZmed and Infervision is on Clinical and Operational Evidence, where AZmed grades A and Infervision grades C. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do AZmed and Infervision grade the same?
The AI Health Index grades AZmed and Infervision the same on several axes, including AI Centrality, Autonomy and Oversight Model and AI Safety and PHI Stewardship. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have AZmed and Infervision not disclosed?
At the last review, at least one of AZmed and Infervision published thin or absent detail on Model Supply Chain Disclosure and AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Compare these per body region and per finding rather than on aggregate claims, since a trauma product and a chest product share almost no performance surface. Both are non United States origin vendors and the index records the same pattern for that group: regulatory effort follows market access while commercial assurance documentation is thinner, so ask for attestations and business associate terms explicitly. Prevalence in your own population determines the false positive burden more than published sensitivity, and neither publishes performance stratified that way.